Drug Search Results
More Filters [+]


Alternative Names: aip-001, aip001, aip 001
Latest Update: 2009-09-24
Latest Update Note: Clinical Trial Update

Product Description

AN-1792 was the first active immunotherapy strategy forÊAlzheimer's disease. AN-1792 consists of synthetic full-length A_Êpeptide with QS-21 adjuvant. The rationale was that AN-1792 would induce an immune response that would remove brain amyloid deposition. (Sourced from: https://www.alzforum.org/therapeutics/an-1792)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AIP-001

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases



Trial Status


Primary Completion Date

Probability of Success

Recent News Events